Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Soham D. Puvvada; Patrick J. Stiff; Michael Leblanc; James R. Cook; Stephen Couban; John P. Leonard; Brad Kahl; Deborah Marcellus; Thomas C. Shea; Jane N. Winter; Hongli Li; Lisa M. Rimsza; Jonathan W. Friedberg; Sonali M. Smith

doi:10.1111/bjh.14100

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Soham D. Puvvada, Patrick J. Stiff, Michael Leblanc, James R. Cook, Stephen Couban, John P. Leonard, Brad Kahl, Deborah Marcellus, Thomas C. Shea, Jane N. Winter, Hongli Li, Lisa M. Rimsza, Jonathan W. Friedberg, Sonali M. Smith

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

Original language	English (US)
Pages (from-to)	686-691
Number of pages	6
Journal	British journal of haematology
Volume	174
Issue number	5
DOIs	https://doi.org/10.1111/bjh.14100
State	Published - Sep 1 2016

Keywords

BCL2
MYC
autologous stem cell transplant
double hit lymphoma
double protein lymphoma

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.14100

Cite this

Puvvada, S. D., Stiff, P. J., Leblanc, M., Cook, J. R., Couban, S., Leonard, J. P., Kahl, B., Marcellus, D., Shea, T. C., Winter, J. N., Li, H., Rimsza, L. M., Friedberg, J. W., & Smith, S. M. (2016). Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British journal of haematology, 174(5), 686-691. https://doi.org/10.1111/bjh.14100

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. / Puvvada, Soham D.; Stiff, Patrick J.; Leblanc, Michael et al.
In: British journal of haematology, Vol. 174, No. 5, 01.09.2016, p. 686-691.

Research output: Contribution to journal › Article › peer-review

Puvvada, SD, Stiff, PJ, Leblanc, M, Cook, JR, Couban, S, Leonard, JP, Kahl, B, Marcellus, D, Shea, TC, Winter, JN, Li, H, Rimsza, LM, Friedberg, JW & Smith, SM 2016, 'Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704', British journal of haematology, vol. 174, no. 5, pp. 686-691. https://doi.org/10.1111/bjh.14100

@article{5d06cc5d65774bdbbdf7a3437b372877,

title = "Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704",

abstract = "Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.",

keywords = "BCL2, MYC, autologous stem cell transplant, double hit lymphoma, double protein lymphoma",

author = "Puvvada, {Soham D.} and Stiff, {Patrick J.} and Michael Leblanc and Cook, {James R.} and Stephen Couban and Leonard, {John P.} and Brad Kahl and Deborah Marcellus and Shea, {Thomas C.} and Winter, {Jane N.} and Hongli Li and Rimsza, {Lisa M.} and Friedberg, {Jonathan W.} and Smith, {Sonali M.}",

note = "Publisher Copyright: {\textcopyright} 2016 John Wiley & Sons Ltd",

year = "2016",

month = sep,

day = "1",

doi = "10.1111/bjh.14100",

language = "English (US)",

volume = "174",

pages = "686--691",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant

T2 - subset analysis of randomized trial intergroup SWOG S9704

AU - Puvvada, Soham D.

AU - Stiff, Patrick J.

AU - Leblanc, Michael

AU - Cook, James R.

AU - Couban, Stephen

AU - Leonard, John P.

AU - Kahl, Brad

AU - Marcellus, Deborah

AU - Shea, Thomas C.

AU - Winter, Jane N.

AU - Li, Hongli

AU - Rimsza, Lisa M.

AU - Friedberg, Jonathan W.

AU - Smith, Sonali M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

AB - Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

KW - BCL2

KW - MYC

KW - autologous stem cell transplant

KW - double hit lymphoma

KW - double protein lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84987735570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987735570&partnerID=8YFLogxK

U2 - 10.1111/bjh.14100

DO - 10.1111/bjh.14100

M3 - Article

C2 - 27072903

AN - SCOPUS:84987735570

SN - 0007-1048

VL - 174

SP - 686

EP - 691

JO - British journal of haematology

JF - British journal of haematology

IS - 5

ER -

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this